Form 4: Phathom Pharmaceuticals Director James Topper Boosts Stake with $14,600 Share Purchase

Phathom Pharmaceuticals, Inc. Director and 10% Owner James N. Topper has acquired an additional 3,780 shares of common stock, signaling increased insider confidence.

Summary

• James N. Topper, a Director and 10% Owner of Phathom Pharmaceuticals, Inc. (PHAT), purchased 3,780 shares of the company's common stock.
• The transaction occurred on May 21, 2025, at a weighted average price of $3.8649 per share, totaling approximately $14,600.
• The shares were acquired in multiple transactions with prices ranging from $3.76 to $3.90.
• Following this transaction, James N. Topper's beneficial ownership, including direct and indirect holdings, totals 5,922,827 shares.
• Indirect holdings include shares held by Frazier Life Sciences X, L.P. (59,403 shares), Frazier Life Sciences IX, L.P. (5,827,415 shares), FHMLS IX, L.L.C (1 share), and Topper Group III LLC (3,912 shares).
• The reporting person disclaims beneficial ownership of securities held by Frazier Life Sciences X, L.P., Frazier Life Sciences IX, L.P., and FHMLS IX, L.L.C. except to the extent of his pecuniary interest therein, as he is one of two managing members of the general partners of these entities.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to a significant insider purchase by a director and 10% owner, indicating strong confidence in the company's valuation and future prospects.

Positives

• A significant purchase by a Director and 10% Owner indicates strong insider confidence in the company's future prospects.
• The acquisition of shares at a weighted average price of $3.8649 suggests management believes the stock is undervalued at current levels.
• The transaction increases the alignment of interests between the director and common shareholders.

Future Outlook

This Form 4 filing does not contain any explicit forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Insider buying, particularly by a director and significant owner, can be interpreted as a positive signal within the pharmaceutical and biotechnology industry, suggesting confidence in the company's drug pipeline, regulatory approvals, or commercialization efforts, especially in a sector often characterized by high R&D costs and regulatory hurdles.

Related Party Transactions

• James N. Topper's beneficial ownership includes shares held indirectly through Frazier Life Sciences X, L.P., Frazier Life Sciences IX, L.P., and FHMLS IX, L.L.C., where he is a managing member of the general partners. He disclaims beneficial ownership except to the extent of his pecuniary interest.
• Shares are also held indirectly through Topper Group III LLC, where the Reporting Person is a manager and has voting and investment power.

Stakeholder Impact

• Shareholders may view this insider purchase as a vote of confidence from a key executive and significant owner, potentially leading to increased investor interest and positive sentiment.
• The transaction aligns the interests of the director more closely with those of other shareholders.

Key Dates

Recommendation

Keywords

Phathom Pharmaceuticals, PHAT, Insider Trading, SEC Form 4, Director Purchase, Stock Acquisition, Biotechnology, Pharmaceuticals, James N. Topper, Frazier Life Sciences